Work

217eP Immunotherapy beyond trials: Dostarlimab in advanced endometrial cancer: A Portuguese multicenter experience

Year: 2025

Type: article

Abstract: Dostarlimab was available in Portugal for advanced or recurrent endometrial cancer post–platinum therapy via early access(EAP) since November 2021, with reimbursement from October 2024; its use with carboplatin and paclitaxel was authorized under EAP in June 2024. Until now, no national real-world data have been reported.

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2025.101300

Authors: M.Q. Pereira, P. Antunes Meireles, I. Miguel, A.R.D.S. Lopes, J.M.C. Rodrigues, M.C. Couto, I.C. Gomes Fernandes, M.T. Crisóstomo, A.G. Zanga, I.S. Soares de Pinho, P.J.T.D. Castro, B.D.S. Castanheira, P. Simões, F. Macedo, R.Q. Ferreira, F. Vaz

Institutions: Instituto Português de Oncologia Francisco Gentil, IPO Porto, Unidade Local de Saúde de Coimbra, Hospital de São João, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Hospital of St. Francis Xavier, Hospital Prof. Dr. Fernando Fonseca, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, Unidade Local de Saúde de Trás-os-Montes e Alto Douro, Hospital Garcia de Orta, Hospital Beatriz Ângelo, Instituto Português de Oncologia de Coimbra Francisco Gentil, Unidade Local de Saúde de São José, Hospital Santo António dos Capuchos

Language: English

Topic: Endometrial and Cervical Cancer Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,340

OpenAlex ID: W7117292571

FWCI:

Cites:

Cited by:

Related to: